151 related articles for article (PubMed ID: 35041097)
21. Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients Before Neoadjuvant Chemotherapy: A Preliminary Study.
Kim EY; Byon WS; Lee KH; Yun JS; Park YL; Park CH; Youn IY; Choi SH; Choi YJ; Kook SH; Do SI
World J Surg; 2018 Feb; 42(2):582-589. PubMed ID: 28808843
[TBL] [Abstract][Full Text] [Related]
22. Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy.
Montagna G; Mamtani A; Knezevic A; Brogi E; Barrio AV; Morrow M
Ann Surg Oncol; 2020 Oct; 27(11):4515-4522. PubMed ID: 32488513
[TBL] [Abstract][Full Text] [Related]
23. Combining Wire Localization of Clipped Nodes with Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer: Preliminary Results from a Prospective Study.
García-Novoa A; Acea-Nebril B; Díaz Carballada C; Bouzón Alejandro A; Conde C; Cereijo Garea C; Varela JR; Santiago Freijanes P; Antolín Novoa S; Calvo Martínez L; Díaz I; Rodríguez Martínez S; Mosquera Oses J
Ann Surg Oncol; 2021 Feb; 28(2):958-967. PubMed ID: 32725521
[TBL] [Abstract][Full Text] [Related]
24. SAVI SCOUT® localization of metastatic axillary lymph node prior to neoadjuvant chemotherapy for targeted axillary dissection: a pilot study.
Baker JL; Haji F; Kusske AM; Fischer CP; Hoyt AC; Thompson CK; Lee MK; Attai D; DiNome ML
Breast Cancer Res Treat; 2022 Jan; 191(1):107-114. PubMed ID: 34652548
[TBL] [Abstract][Full Text] [Related]
25. Carbon nanoparticles localized clipped node dissection combined with sentinel lymph node biopsy with indocyanine green and methylene blue after neoadjuvant therapy in node positive breast cancer in China: initial results of a prospective study.
Yang X; Li Y; Ren XT; Fan L; Hua B
World J Surg Oncol; 2023 Jul; 21(1):214. PubMed ID: 37480099
[TBL] [Abstract][Full Text] [Related]
26. Factors Influencing Non-sentinel Lymph Node Involvement in Patients with Positive Sentinel Lymph Node(s) After Neoadjuvant Chemotherapy for Breast Cancer.
Sanders SB; Hoskin TL; Stafford AP; Boughey JC
Ann Surg Oncol; 2022 Nov; 29(12):7769-7778. PubMed ID: 35834142
[TBL] [Abstract][Full Text] [Related]
27. Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of clipped node improve our results?
Alarcón M; Buch E; Julve A; Hernandorena M; Tajahuerce M; Rodríguez H; Bermejo B; Ramírez J; Burgués O; Díaz S; Alcalá GM; Ortega J
Surgeon; 2021 Dec; 19(6):344-350. PubMed ID: 33663946
[TBL] [Abstract][Full Text] [Related]
28. Update on sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer patient.
Franceschini G; Di Leone A; Sanchez AM; D'Archi S; Terribile D; Magno S; Scardina L; Masetti R
Ann Ital Chir; 2020; 91():465-468. PubMed ID: 32312945
[TBL] [Abstract][Full Text] [Related]
29. Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer.
Simons JM; van Pelt MLMA; Marinelli AWKS; Straver ME; Zeillemaker AM; Pereira Arias-Bouda LM; van Nijnatten TJA; Koppert LB; Hunt KK; Smidt ML; Luiten EJT; van der Pol CC
Br J Surg; 2019 Nov; 106(12):1632-1639. PubMed ID: 31593294
[TBL] [Abstract][Full Text] [Related]
30. Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation.
Takei H; Yoshida T; Kurosumi M; Inoue K; Matsumoto H; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Kubo K; Oba H; Nagai S; Tabei T
Int J Clin Oncol; 2013 Jun; 18(3):547-53. PubMed ID: 22588780
[TBL] [Abstract][Full Text] [Related]
31. Ongoing clinical trials on axillary management.
Kouloura A; Lanitis S; Filopoulos E; Angelopoulos MP; Kosmidis SP; Arkadopoulos N
Minerva Chir; 2020 Dec; 75(6):408-418. PubMed ID: 33345527
[TBL] [Abstract][Full Text] [Related]
32. SPECT/CT Lymphoscintigraphy Accurately Localizes Clipped and Sentinel Nodes After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer.
Dilege E; Celik B; Falay O; Boge M; Sucu S; Toprak S; Agcaoglu O; Kapucuoglu N; Demirkol O
Clin Nucl Med; 2023 Jul; 48(7):594-599. PubMed ID: 37075247
[TBL] [Abstract][Full Text] [Related]
33. Feasibility and validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Definitive results.
Flores-Funes D; Aguilar-Jiménez J; Martínez-Gálvez M; Ibáñez-Ibáñez MJ; Carrasco-González L; Gil-Izquierdo JI; Chaves-Benito MA; Ayala-De La Peña F; Nieto-Olivares A; Aguayo-Albasini JL
Surg Oncol; 2021 Sep; 38():101636. PubMed ID: 34303211
[TBL] [Abstract][Full Text] [Related]
34. Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed?
Baker JL; Muhsen S; Zabor EC; Stempel M; Gemignani ML
Ann Surg Oncol; 2019 Feb; 26(2):336-342. PubMed ID: 30506175
[TBL] [Abstract][Full Text] [Related]
35. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
Classe JM; Loaec C; Gimbergues P; Alran S; de Lara CT; Dupre PF; Rouzier R; Faure C; Paillocher N; Chauvet MP; Houvenaeghel G; Gutowski M; De Blay P; Verhaeghe JL; Barranger E; Lefebvre C; Ngo C; Ferron G; Palpacuer C; Campion L
Breast Cancer Res Treat; 2019 Jan; 173(2):343-352. PubMed ID: 30343457
[TBL] [Abstract][Full Text] [Related]
36. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
Boughey JC; Yu H; Dugan CL; Piltin MA; Postlewait L; Son JD; Edmiston KK; Godellas CV; Lee MC; Carr MJ; Tonneson JE; Crown A; Lancaster RB; Woriax HE; Ewing CA; Chau HS; Patterson AK; Wong JM; Alvarado MD; Yang RL; Chan TW; Sheade JB; Ahrendt GM; Larson KE; Switalla K; Tuttle TM; Tchou JC; Rao R; Tamirisa N; Singh P; Gould RE; Terando A; Sauder C; Hewitt K; Chiba A; Esserman LJ; Mukhtar RA
Ann Surg Oncol; 2023 Oct; 30(11):6401-6410. PubMed ID: 37380911
[TBL] [Abstract][Full Text] [Related]
37. The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.
Noguchi M; Inokuchi M; Yokoi-Noguchi M; Morioka E
Breast Cancer; 2022 Mar; 29(2):209-215. PubMed ID: 34591289
[TBL] [Abstract][Full Text] [Related]
38. Decreasing Use of Axillary Dissection in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Nguyen TT; Hoskin TL; Day CN; Degnim AC; Jakub JW; Hieken TJ; Boughey JC
Ann Surg Oncol; 2018 Sep; 25(9):2596-2602. PubMed ID: 29978369
[TBL] [Abstract][Full Text] [Related]
39. Sentinel Lymph Node Removal After Neoadjuvant Chemotherapy in Clinically Node-Negative Patients: When to Stop?
Murphy BL; Jakub JW; Asaad M; Day CN; Hoskin TL; Habermann EB; Boughey JC
Ann Surg Oncol; 2021 Feb; 28(2):888-893. PubMed ID: 32816252
[TBL] [Abstract][Full Text] [Related]
40. Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy.
Leonardi MC; Arrobbio C; Gandini S; Volpe S; Colombo F; La Rocca E; Galimberti V; Kahler-Ribeiro-Fontana S; Fodor C; Dicuonzo S; Rojas DP; Zerella MA; Morra A; Montagna E; Colleoni M; Mazzarol G; Travaini LL; Zaffaroni M; Veronesi P; Orecchia R; Jereczek-Fossa BA
Radiother Oncol; 2021 Oct; 163():128-135. PubMed ID: 34461184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
